#United States #New York #Levi & Korsinsky #Vistagen #VTGN

Vistagen Therapeutics Class Action Lawsuit Update

On February 25, 2026, Levi & Korsinsky, LLP announced a crucial deadline for shareholders of Vistagen Therapeutics, Inc. (ticker: VTGN) regarding a class action lawsuit linked to alleged securities fraud. Investors who incurred losses from April 1, 2024, to December 16, 2025, are encouraged to participate in the action, which seeks to hold defendants accountable for misleading information disseminated about the company’s clinical trials.

Understand the Class Action

The pending class action suit addresses serious grievances from investors who believed they were misled by the company regarding the efficacy of fasedienol, a treatment targeting social anxiety disorder. Accusations from the class action suggest that during the pertinent period, Vistagen's representations were overly positive, failing to disclose critical adverse aspects of their Phase 3 PALISADE-3 trial. At the heart of the lawsuit is the significant drop in Vistagen’s stock price after the announcement on December 17, 2025, that the trial did not meet its primary endpoint, resulting in a dramatic decline of over 80% in share value, effectively plummeting from $4.36 to $0.86 per share.

Important Deadline for Investors

Shareholders affected by these developments are reminded of the deadline to act. Plaintiffs must request to be appointed as lead plaintiff by March 16, 2026. However, potential recovery for those who suffered losses does not require lead plaintiff status, meaning participation can occur without formal obligation.

What to Expect

Levi & Korsinsky reassures class members that there will be no out-of-pocket costs to engage in this lawsuit. The firm has a longstanding reputation for successfully advocating on behalf of aggrieved shareholders, having secured substantial recoveries in similar cases over its twenty-year history.

Why Levi & Korsinsky?

With a dedicated team comprising over 70 employees, Levi & Korsinsky has established itself among the top securities litigation firms in the United States, as evidenced by their consistent recognition in ISS Securities Class Action Services' Top 50 Report.

How to Get Involved

For those interested in joining this class action and seeking more details, direct communication with attorney Joseph E. Levi is encouraged. Investors may reach out via email at [email protected], or by phone at (212) 363-7500. Comprehensive information regarding the case can also be found on their dedicated webpage.

As this class action unfolds, it serves as a significant reminder for investors to stay informed about their rights and the avenues available to address potential financial grievances. Now is the time for impacted shareholders to consider their options and take appropriate steps to protect their investments in Vistagen Therapeutics.

For further inquiries, legal advice, or to start the process of joining this action, reach out to Levi & Korsinsky to ensure your voice is heard in this critical matter.